Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer

JAMA Oncology - United States
doi 10.1001/jamaoncol.2018.4465
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Medical Association (AMA)

Related search

FOLFIRI Plus Panitumumab in the Treatment of Wild-Type KRAS and Wild-Type NRAS Metastatic Colorectal Cancer

World Journal of Surgical Oncology
SurgeryOncology
2018English

P16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients With Metastatic Colorectal Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2016English

PCN70 Cost-Effectiveness of Cetuximab and Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) for Patients With Kras Wild-Type Tumours in the United Kingdom

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Efficacy of Continued Cetuximab for Unresectable Metastatic Colorectal Cancer After Disease Progression During First-Line Cetuximab-Based Chemotherapy: A Retrospective Cohort Study

Oncotarget
Oncology
2016English

EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy

Cancers
Cancer ResearchOncology
2020English

Impact of Primary Tumour Location on Efficacy of Bevacizumab Plus Chemotherapy in Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

Cetuximab in First Line Treatment of Metastatic Colorectal Cancer

Farmeconomia. Health economics and therapeutic pathways
2012English

Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study

Clinical Colorectal Cancer
OncologyGastroenterology
2017English

Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) Is an Independent Prognostic Marker in Wild-Type KRAS Metastatic Colorectal Cancer After Colorectal Liver Metastasectomy

BMC Cancer
Cancer ResearchOncologyGenetics
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy